ELE-101 – Beckley Psytech’s IV formulation of psilocin
The procurement was largely based on the potential of ELE-101, Eleusis’ IV formulation of psilocin which the team believes may have a shorter treatment duration and less variability compared with oral forms of psilocybin.
Members of Eleusis’ management team were subsequently integrated into the organisation’s C-suite, with Senior Vice President Rob Conley transitioning into Beckley Psytech’s Chief Scientific Officer.
Rob Conley brings to the table a wealth of drug development experience, having previously served as Chief Scientific Officer for Neuroscience at Eli Lilly. To discuss the potential of ELE-101 to treat major depressive disorder cost-effectively, PSYCH spoke with Beckley Psytech’s new CSO.READ MORE